Ocugen (OCGN) said Wednesday that the European Medicines Agency has granted orphan medicinal product designation for its experimental drug OCU410ST to treat ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.
Orphan medicinal product designation in Europe provides benefits such as protocol assistance, reduced fees, research grants, and 10 years of market exclusivity upon approval.
The drug developer said it plans to pursue an accelerated marketing authorization application for OCU410ST.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments